腹腔镜手术治疗巨大肝血管瘤患者疗效研究*

doi:10.3969/j.issn.1672-5069.2023.04.028

摘要/Abstract

摘要： 目的分析比较采用腹腔镜手术与开腹手术治疗巨大肝血管瘤(GHH)患者的临床效果。方法 2012年6月～2022年1月我科诊治的GHH患者54例,其中30例接受腹腔镜手术,另24例接受开腹手术。常规检测血清C-反应蛋白(CRP)和降钙素原(PCT)水平。结果腔镜组肿瘤直径及肝左叶、肝右叶和左右叶肿瘤占比分别为(12.2±2.5)cm、30.0%、46.7%和23.3%,与开腹组比,无显著性差异【分别为(11.3±1.9)cm、29.2%、54.2%和16.7%,P>0.05】;腹腔镜组术中失血量为(188.3±70.5)ml,显著少于开腹组【(285.6±116.5)ml,P<0.05】,而肝门阻断时间为(26.2±10.2)min,显著长于开腹组【(15.2±9.7)min, P<0.05】;腹腔镜组腹腔引流量为(180.5±72.6)ml,显著少于开腹组【(282.3±102.8)ml,P<0.05】,术后住院日为(8.2±2.8)d,显著短于开腹组【(11.6±3.2)d,P<0.05】,血清C-反应蛋白(CRP)和降钙素原(PCT)分别为(31.8±14.4)mg/L和(0.1±0.1)ng/ml,显著低于开腹组【分别为(56.4±20.5)mg/L和(0.2±0.1)ng/ml,P<0.05】。结论采用腹腔镜手术治疗GHH患者是安全可行的,相较于开腹手术具有全身炎症反应轻和术后恢复快的优势。

关键词: 巨大肝血管瘤, 腹腔镜手术, 肝门阻断时间, 降钙素原, 治疗

Abstract: Objective This study was to conducted to compare the clinical efficacy of laparoscopic hepatectomy (LH) and traditional open surgery (OS) in the treatment of patients with giant hepatic hemangioma (GHH). Methods 54 patients with GHH were encountered in our hospital between June 2012 and January 2022, and were divided into two groups, receiving LH (n=30) or traditional open surgery (n=24) treatment. The clinical data before and after operation in the two groups were compared. Results The tumor diameter, the percentages of tumors in the left, right and both lobes in LH-surgery-treated patients were (12.2±2.5)cm, 30.0%, 46.7% and 23.3%, all not significantly different compared to [(11.3±1.9)cm, 29.2%, 54.2% and 16.7%, respectively, P>0.05] in open surgery-treated patients; the intra-operational blood loss in LH-treated patients was (188.3±70.5)ml, much less than [(285.6±116.5)ml, P<0.05], while the blocking time of hilus hepatis was (26.2±10.2)min, much longer than [(15.2±9.7)min, P<0.05] in open surgery-treated patients; the drainage volume in LH-treated patients was (180.5±72.6)ml, much less than [(282.3±102.8)ml, P<0.05], the post-operational hospital stay was (8.2±2.8)days, significantly shorter than [(11.6±3.2)days, P<0.05], and serum C-reactive protein and procalcitonin levels were (31.8±14.4)mg/L and (0.1±0.1)ng/ml, significantly lower than [(56.4±20.5)mg/L and (0.2±0.1)ng/ml, respectively, P<0.05] in open surgery-treated patients. Conclusion The application of LH in the treatment of patients with GHH is safe and feasible, which might be lead to mild systemic inflammatory reactions, and relatively faster recovery after operation.

Key words: Giant hepatic hemangioma, Laparoscopic hepatectomy, Blocking hilus hepatis, Procalcitonin, Therapy

朱加猛, 范丽琴, 尹力, 吴柏华. 腹腔镜手术治疗巨大肝血管瘤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 564-567.

Zhu Jiameng, Fan Liqin, Yin Li, et al. Laparoscopic hepatectomy in the treatment of patients with giant hepatic hemangioma[J]. Journal of Practical Hepatology, 2023, 26(4): 564-567.

参考文献

[1] Noh OK, Kim SS, Yang MJ, et al. Treatment and prognosis of hepatic epithelioid hemangioendothelioma based on SEER data analysis from 1973 to 2014. Hepatobiliary Pancreat Dis Int, 2020, 19(1):29-35.
[2] Klotz T, Montoriol PF, Da Ines D, et al. Hepatic haemangioma: common and uncommon imaging features. Diagn Interv Imaging, 2013, 94(9):849-859.
[3] Kuroda T, Kumagai M, Nosaka S, et al. Critical infantile hepatic hemangioma: results of a nationwide survey by the Japanese Infantile Hepatic Hemangioma Study Group. J Pediatr Surg, 2011, 46(12):2239-2243.
[4] Makamure J, Zhao D, Liu Y, et al. Hepatic hemangioma with arterioportal shunt: Prevalence and lesion characteristics based on DSA, CT and MR imaging. EurJ Radiol, 2019, 121:108715.
[5] Liu Z, Yi L, Chen J, et al. Comparison of the clinical and MRI features of patients with hepatic hemangioma, epithelioid hemangioendothelioma, or angiosarcoma. BMC Med Imaging, 2020, 20(1):71.
[6] Dong W, Qiu B, Xu H, et al. Invasive management of symptomatic hepatic hemangioma. Eur J Gastroenterol Hepatol, 2019, 31(9):1079-1084.
[7] Jinhuan Y, Gang D, Binyao S, et al. Is laparoscopic hepatectomy suitable for giant hepatic hemangioma larger than 10 cm in diameter? Surg Endosc, 2020, 34(3):1224-1230.
[8] Yan C, Li BH, Sun XT, et al. Laparoscopic hepatectomy is superior to open procedures for hepatic hemangioma. Hepatobiliary Pancreat Dis Int, 2020, S1499-3872(20)30198-30203.
[9] Liu JL, Gao XP, Chen KS, et al. Huge fetal hepatic hemangioma: prenatal diagnosis on ultrasound and prognosis. BMC Pregnancy Child Birth, 2018, 18(1):2.
[10] Wang Z, Tang X, Qi X, et al. Feasibility, safety, and efficacy of ultrasound-guided percutaneous microwave ablation for giant hepatic hemangioma. Int J Hyperthermia, 2018,35(1):246-252.
[11] Katayama H, Kurokawa Y, Nakamura K, et al. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today, 2016, 46(6):668-685.
[12] Veerankutty FH, Rather SA, Yeldho V, et al. Totally laparoscopic resection of an extremely giant hepatic hemangioma. Surg J (N Y), 2019, 5(3):e110-e112.
[13] Liu Q, Liu F, Ding J, et al. Surgical outcomes and quality of life between laparoscopic and open approach for hepatic hemangioma: A propensity score matching analysis. Medicine (Baltimore), 2019, 98(6):e14485.
[14] Lee WJ, Chan CP, Wang BY. Recent advances in laparoscopic surgery. Asian J Endosc Surg, 2013, 6(1):1-8.
[15] Moloo H, Haggar F, Coyle D, et al. Hand assisted laparoscopic surgery versusconventional laparoscopy for colorectal surgery. Cochrane Database Syst Rev, 2010, (10):CD006585.
[16] Harumatsu T, Nagai T, Yano K, et al. Differential advantage of liver retraction methods in laparoscopic fundoplication for neurologically impaired patients: a comparison of three kinds of procedures. Pediatr Surg Int, 2020, 36(5):591-596.
[17] Hayashi H, Ozaki N, Ogawa K, et al. Assessing the economic advantage of laparoscopic vs. open approaches for colorectal cancer by a propensity score matching analysis. Surg Today, 2018, 48(4):439-448.
[18] Taniai T, Haruki K, Hamura R, et al. The prognostic significance of c-reactive protein-to-lymphocyte ratio in colorectal liver metastases. J Surg Res, 2021, 258:414-421.
[19] Sato S, Sato S, Tsuzura H, et al. Elevated serum procalcitonin levels and their association with the prognosis of patients with liver cirrhosis. Eur J Gastroenterol Hepatol, 2020, 32(9):1222-1228.
[20] Sugihara T, Koda M, Okamoto T, et al. Serum procalcitonin in patients with acute liver failure. Yonago Acta Med, 2017,60(1):40-46.

腹腔镜手术治疗巨大肝血管瘤患者疗效研究^*

Laparoscopic hepatectomy in the treatment of patients with giant hepatic hemangioma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨凯, 张凯, 汪勇. 应用聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎患者血清sVAP-1和SAA水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(4): 484-487.
[2]	王卓雅, 吴洋鹏, 黄益桃. 多烯磷脂酰胆碱联合脂必泰治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 496-499.
[3]	甄永利, 张亚飞, 张振华. 自身免疫性肝病患者甲状腺功能变化及其对治疗应答的影响^*[J]. 实用肝脏病杂志, 2023, 26(4): 508-511.
[4]	唐新华, 唐慧京, 黄成军, 李观. 恩替卡韦治疗血清HBeAg阳性高病毒载量乙型肝炎病毒携带者合并肺结核患者预防抗痨治疗引起的药物性肝损伤效果研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 516-519.
[5]	丁闪闪, 丁凯, 姜宁. 索磷布韦联合维帕他韦治疗丙型肝炎肝硬化患者疗效及安全性分析^*[J]. 实用肝脏病杂志, 2023, 26(4): 536-539.
[6]	袁小兵, 陈慰慰, 刘小莉, 姜铭, 范向军. 根治性肝叶切除术治疗肝细胞癌患者外周血自然杀伤细胞活力变化及其临床意义探讨[J]. 实用肝脏病杂志, 2023, 26(4): 544-547.
[7]	黄昱, 王卓, 任承纲, 张耀, 刘杨旸, 樊华, 何梅峰. PTGD后不同时间行LC治疗急性结石性胆囊炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 568-571.
[8]	曾林, 张勇, 罗九宝, 吉彩云, 丹娜. LC术后应用疏利通泄汤治疗慢性胆囊炎合并胆结石患者对胃肠功能的影响^*[J]. 实用肝脏病杂志, 2023, 26(4): 572-575.
[9]	刘泽军, 慕海峰, 陈升宝, 王春, 徐刚. LC联合LCBDE同步手术治疗胆囊结石合并胆总管结石患者临床疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 576-579.
[10]	郑峰, 李彦荣, 罗卫军, 张晓超. 经胆囊后三角入路和经胆囊三角入路腹腔镜胆囊切除术治疗胆囊结石伴慢性胆囊炎患者疗效及对血清炎症因子的影响^*[J]. 实用肝脏病杂志, 2023, 26(4): 580-583.
[11]	周红飞, 陈钟, 顾宏, 沙德胜. 胆管空肠Roux-en-Y吻合联合皮下空肠盲袢埋藏术治疗肝胆管结石患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 584-587.
[12]	张绍全, 林炳亮. 肠道菌群与肝硬化研究进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 313-316.
[13]	张丹蕾, 徐静. 艾米替诺福韦治疗慢性乙型肝炎患者早期疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 336-339.
[14]	郭晓玲, 张耀武, 李梦桃, 张辉. 恩替卡韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 340-343.
[15]	王云云, 吴万锋, 李黎. 直接抗病毒药物治疗基因1b型慢性丙型肝炎合并2型糖尿病患者疗效及对血糖控制的影响^*[J]. 实用肝脏病杂志, 2023, 26(3): 344-347.